Management ChangeApr 22, 2026, 07:03 AM
Tenax Therapeutics Appoints Thomas R. Staab, II as CFO
AI Summary
Tenax Therapeutics, Inc. announced the appointment of Thomas R. Staab, II as its new Chief Financial Officer, effective May 11, 2026. Mr. Staab brings over 25 years of leadership experience in management and corporate finance roles within the healthcare industry, having previously served as CFO for LENSAR, BioCryst Pharmaceuticals, and Inspire Pharmaceuticals. He will replace Thomas McGauley, who served as interim CFO since December 2024. The company also announced inducement equity awards for Mr. Staab, including 10,000 restricted stock units and options to purchase 450,000 shares of common stock.
Key Highlights
- Thomas R. Staab, II appointed Chief Financial Officer, effective May 11, 2026.
- Mr. Staab brings over 25 years of financial and executive experience in healthcare.
- He replaces interim CFO Thomas McGauley.
- Received inducement equity awards: 10,000 restricted stock units and options for 450,000 shares.
Price Impact
More from TENX